Phibro Animal Health Corporation (PAHC) is an internationally recognized leader in the field of animal health solutions. The company is headquartered in Teaneck, New Jersey, and was established in 1916. Over the years, it has made a significant impact in improving animal health with a wide range of products and services, making it an essential partner for farmers, veterinarians, and animal producers worldwide.
This public company is known for developing, manufacturing, and supplying a wide variety of animal health and nutrition products. The product line includes mineral nutrition products, animal vaccines, feed additives, and other products which boost the productivity and overall health of poultry, swine, cattle, and other livestock. Additionally, PAHC focuses on innovation and new product development.
Phibro Animal Health Corporation provides more than 550 product formulations in over 100 countries around the globe. Apart from its primary business in animal health and nutrition, the company also provides performance products for use in industries like personal care, automotive, oil, and chemical industries. The company operates through three main segments: Animal Health, Mineral Nutrition, and Performance Products.
Phibro's Animal Health segment focuses on the development and sale of products for food animals and pets. It produces antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. Animal Health products are used in the poultry, swine, cattle and aquaculture sectors, and to a lesser extent, in the pet health sector.
The Mineral Nutrition segment specializes in the manufacturing and marketing of an extensive range of inorganic minerals and nutritional products for use in both animal and industrial applications. Performance Products, on the other hand, specialize in the production of specialty products for use in the personal care, automotive, industrial chemical and oil industries.
Phibro continuously strives to exceed customer expectations by delivering value-added products and services that enhance the quality, abundance, and safety of the global food supply. The company’s mission is to strive for continuous improvement and innovation in animal health, empowered by a dedicated team of research scientists and technologists. With an unwavering commitment to integrity, Phibro Animal Health Corporation is continually improving animal health and aiding in global food production.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Phibro Animal Health CFO David Glenn was granted 3,482 shares on August 6, 2026, which increased his total holdings in the company to 54,959 shares. This award represents approximately 6.3% of his total share position after the transaction. The transaction was classified under code A, indicating it was an award or grant from PHIBRO ANIMAL HEALTH CORP (NASDAQ:PAHC).
Phibro Animal Health Corp awarded 3,726 shares to its COO, Miller Larry Lee, on August 6, 2026. This grant increased his total holdings in the company to 38,275 shares, representing approximately 9.7% of his new share position. The transaction was classified under code A and was disclosed via a Form 4/A filing.
Phibro Animal Health Corporation (NASDAQ: PAHC) filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with the SEC on August 26, 2026. The report details key financial information including outstanding shares of Class A and Class B common stock, their market value held by non-affiliates, and outlines various risk factors that could impact the company's future performance. The company is classified as a large accelerated filer, and its proxy statement will be incorporated by reference within 120 days post fiscal year-end.